Pediatrix® Medical Group to Host National Neonatology Meetings Feb. 19-24
High preterm birth rate underscores the importance of continuing education on the care of premature and critically ill newborns FORT LAUDERDALE, Fla.–(BUSINESS... Read more.
Mexico Loyalty Programs Market Databook Q1 2024 – A $4.11 Billion Market by 2028, Registering CAGR of 9.8% During 2024-2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Mexico Loyalty Programs Market Intelligence and Future Growth Dynamics Databook – 50+ KPIs on Loyalty Programs... Read more.
Hestan Launches Cutting Edge E-levated Kitchen
Electric & Induction Appliances Offer Unrivaled Technology for Home Cooks ANAHEIM, Calif.–(BUSINESS WIRE)–Hestan, premium commercial and residential... Read more.
Tilly’s, Inc. to Report Fiscal 2023 Fourth Quarter Operating Results on March 14, 2024
IRVINE, Calif.–(BUSINESS WIRE)–Tilly’s, Inc. (NYSE: TLYS) today announced that the company will release its financial results for the fourth quarter... Read more.
Inyarek Partners Launches to Redefine Energy Transition Investing
Private equity firm leverages extensive energy sector experience to deploy strategic capital into the energy transition, transforming asset development opportunities... Read more.
Herc Holdings Reports Strong Full Year 2023 Results and Announces 2024 Full Year Guidance
Fourth Quarter 2023 Highlights Record total revenues of $831 million, an increase of 6% Net income decreased 7% to $91 million, or $3.20 per diluted share Adjusted... Read more.
Rimere Receives $10 Million Strategic Investment from Clean Energy
Rimere’s plasma technology produces clean hydrogen and graphene; decarbonizes natural gas infrastructure. NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Rimere,... Read more.
SITE Centers Reports Fourth Quarter and Full-Year 2023 Results and Declares First Quarter Dividend
BEACHWOOD, Ohio–(BUSINESS WIRE)–SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers in suburban, high household income communities,... Read more.
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug... Read more.
Injectable Hematology Growth Factors Report 2024 – Evolution in Therapeutic Care – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Injectable Hematology Growth Factors Report” has been added to ResearchAndMarkets.com’s offering. This... Read more.